Sugar and fat, a recipe for disaster. New guidelines for the pharmacological management of diabetic dyslipidaemia.
Australia is embarking upon a more sophisticated approach to lipid-lowering, which is of particular relevance to those with diabetes. Diabetic dyslipidaemia is common and is usually managed in general practice. A step approach focusing on case finding, confirmation of diagnosis, lifestyle modification and pharmacological intervention should be cost effective in this high risk population (Figure 4). Although the focus of this review has been on diabetic dyslipidaemia, management should always consider overall cardiovascular risk.
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D005194:Family Practice; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D008019:Life Style; D017410:Practice Guidelines as Topic; D012307:Risk Factors
D000924:Anticholesteremic Agents